Stockholders' Equity Attributable to Parent of Nurix Therapeutics, Inc. from 30 Nov 2018 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Nurix Therapeutics, Inc. quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 30 Nov 2018 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 30 Nov 2025 was $538,747,000, a 2.2% increase year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $538,747,000 +$11,754,000 +2.2% 30 Nov 2025 10-K 28 Jan 2026 2025 FY
Q3 2025 $372,252,000 -$4,604,000 -1.2% 31 Aug 2025 10-Q 09 Oct 2025 2025 Q3
Q2 2025 $447,603,000 +$76,910,000 +21% 31 May 2025 10-Q 09 Oct 2025 2025 Q3
Q1 2025 $480,917,000 +$312,169,000 +185% 28 Feb 2025 10-Q 09 Oct 2025 2025 Q3
Q4 2024 $526,993,000 +$326,500,000 +163% 30 Nov 2024 10-K 28 Jan 2026 2025 FY
Q3 2024 $376,856,000 +$143,039,000 +61% 31 Aug 2024 10-Q 09 Oct 2025 2025 Q3
Q2 2024 $370,693,000 +$110,772,000 +43% 31 May 2024 10-Q 09 Oct 2025 2025 Q3
Q1 2024 $168,748,000 -$105,304,000 -38% 29 Feb 2024 10-Q 09 Oct 2025 2025 Q3
Q4 2023 $200,493,000 -$103,203,000 -34% 30 Nov 2023 10-K 28 Jan 2026 2025 FY
Q3 2023 $233,817,000 -$108,728,000 -32% 31 Aug 2023 10-Q 11 Oct 2024 2024 Q3
Q2 2023 $259,921,000 -$6,818,000 -2.6% 31 May 2023 10-Q 11 Oct 2024 2024 Q3
Q1 2023 $274,052,000 -$31,865,000 -10% 28 Feb 2023 10-Q 11 Oct 2024 2024 Q3
Q4 2022 $303,696,000 -$38,606,000 -11% 30 Nov 2022 10-K 28 Jan 2026 2025 FY
Q3 2022 $342,545,000 -$32,672,000 -8.7% 31 Aug 2022 10-Q 12 Oct 2023 2023 Q3
Q2 2022 $266,739,000 -$131,439,000 -33% 31 May 2022 10-Q 12 Oct 2023 2023 Q3
Q1 2022 $305,917,000 +$35,784,000 +13% 28 Feb 2022 10-Q 12 Oct 2023 2023 Q3
Q4 2021 $342,302,000 +$52,033,000 +18% 30 Nov 2021 10-K 28 Jan 2025 2024 FY
Q3 2021 $375,217,000 +$67,597,000 +22% 31 Aug 2021 10-Q 06 Oct 2022 2022 Q3
Q2 2021 $398,178,000 +$459,704,000 31 May 2021 10-Q 06 Oct 2022 2022 Q3
Q1 2021 $270,133,000 +$339,935,000 28 Feb 2021 10-Q 06 Oct 2022 2022 Q3
Q4 2020 $290,269,000 +$347,983,000 30 Nov 2020 10-K 09 Feb 2023 2022 FY
Q3 2020 $307,620,000 +$352,060,000 31 Aug 2020 10-Q 14 Oct 2021 2021 Q3
Q2 2020 $61,526,000 -$19,329,000 -46% 31 May 2020 10-Q 14 Oct 2021 2021 Q3
Q1 2020 $69,802,000 -$30,438,000 -77% 29 Feb 2020 10-Q 14 Oct 2021 2021 Q3
Q4 2019 $57,714,000 -$20,867,000 -57% 30 Nov 2019 10-K 28 Jan 2022 2021 FY
Q3 2019 $44,440,000 31 Aug 2019 10-Q 14 Oct 2020 2020 Q3
Q2 2019 $42,197,000 31 May 2019 10-Q 14 Oct 2020 2020 Q3
Q1 2019 $39,364,000 28 Feb 2019 10-Q 14 Oct 2020 2020 Q3
Q4 2018 $36,847,000 30 Nov 2018 10-K 28 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.